Wong Anselm, Graudins Andis, Kerr Fergus, Greene Shaun L
Victorian Poisons Information Centre, Austin Hospital, Melbourne, Victoria, Australia; Austin Toxicology Service, Austin Hospital, Melbourne, Victoria, Australia.
Emerg Med Australas. 2014 Apr;26(2):183-7. doi: 10.1111/1742-6723.12200.
The present study aims to study the implications for resource utilisation if Australia adopted recent revised UK treatment guidelines for paracetamol poisoning.
Retrospective database review of paracetamol toxicity presentations and calls from the Victorian Poisons Information Centre (VPIC) and Austin Hospital, Victoria, Australia, from 1 January 2010 to 31 December 2011. There were 200 presentations at the Austin Hospital, and the VPIC received 4272 calls regarding paracetamol toxicity. An analytical model was designed to estimate the cost of this additional treatment and referral to hospital. The main outcome measures were the potential increase in number of admissions requiring treatment with N-acetylcysteine (NAC), costs involved and increased number of referrals to hospitals by the VPIC.
Twenty-five (12.5%, 95% confidence interval 8.4-17.6%, P < 0.01) patients in our study who did not qualify for NAC therapy based upon the current Australasian paracetamol treatment guideline would have received it if the revised UK guideline was followed. Eighteen (72%) of these presented with acute single ingestions of paracetamol. No patients re-presented to our hospital with acute liver injury or required admission to the liver transplant unit.
Alignment of current Australian paracetamol treatment guidelines with those in the UK would result in an increase in ED attendances as directed by Poisons Information Centres and hospital admissions for antidotal treatment. This would be associated with increased health expenditure and inpatient bed utilisation. The present study does not support the clinical need for adoption of UK paracetamol treatment guidelines in Australia.
本研究旨在探讨如果澳大利亚采用英国近期修订的对乙酰氨基酚中毒治疗指南,对资源利用会产生何种影响。
对2010年1月1日至2011年12月31日期间澳大利亚维多利亚州中毒信息中心(VPIC)和奥斯汀医院的对乙酰氨基酚中毒病例及相关电话进行回顾性数据库分析。奥斯汀医院有200例病例,VPIC接到4272个关于对乙酰氨基酚中毒的电话。设计了一个分析模型来估算这种额外治疗和转诊至医院的费用。主要观察指标为需要用N - 乙酰半胱氨酸(NAC)治疗的住院人数潜在增加量、相关费用以及VPIC转诊至医院的人数增加量。
按照目前澳大利亚对乙酰氨基酚治疗指南不符合NAC治疗标准的25例(12.5%,95%置信区间8.4 - 17.6%,P < 0.01)患者,如果遵循修订后的英国指南将会接受NAC治疗。其中18例(72%)为对乙酰氨基酚急性单次摄入。没有患者因急性肝损伤再次到我院就诊或需要入住肝移植病房。
使澳大利亚目前的对乙酰氨基酚治疗指南与英国指南保持一致,将导致中毒信息中心指导下的急诊科就诊人数增加以及接受解毒治疗的住院人数增加。这将伴随着医疗支出增加和住院床位利用率提高。本研究不支持在澳大利亚采用英国对乙酰氨基酚治疗指南的临床必要性。